Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85466 | 1.00 | ALK (0.43) | ALKDPP4CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL6979570 | 0.84 | LTA4H (0.47) | ALKCHRNB4CHRNA3CHRNA7LTA4H | |
| SCHEMBL7845697 | 0.84 | LTA4H (0.47) | ALKCHRNB4CHRNA3CHRNA7LTA4H | |
| SCHEMBL25155912 | 0.84 | ALK (0.45) | ALKCHRNB4CHRNA3L3MBTL1 | |
| SCHEMBL4322026 | 0.82 | LTA4H (0.56) | ALKLTA4H | |
| SCHEMBL85414 | 0.81 | KMT2A (0.48) | ALKL3MBTL1 | |
| SCHEMBL92405 | 0.81 | PKM (0.44) | ALKL3MBTL1 | |
| SCHEMBL14254443 | 0.80 | NOS3 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25155637 | 0.79 | ALK (0.45) | ALKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15075264 | 0.77 | EGFR (0.44) | ALKCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ALK 1600/4885DPP4 1005/4885CHRNB2 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.